Copy to clipboard 
Treace Medical reported 3Q25 orthopedic sales of $50.2 million, up 11.4% compared to the third quarter of 2024. For the first nine months of the year, the company generated $150.2 million in orthopedic sales, up 6.8% compared to the prior period.
The company has spent 2025 expanding its portfolio so it could compete for 100% of bunion cases. While the strategy has generally worked (case volume up mid-single-digits in the third quarter), Treace experienced pressure on its Lapiplasty volumes as surgeons and patients shift toward minimally invasive osteotomies.
Additionally, the company’s survey of its surgeons indicated a 7% volume decline year-over-year as patients defer elective procedures, especially those with commercial insurance.
Finally, Treace benefitted from one-time stocking orders from distributors, pulling about $3 million forward from expected fourth quarter revenues.
All told, the headwinds caused Treace to revise its guidance downward to revenues between $211 million and $213 million, representing growth between 1% and 2%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $50.2 | $45.1 | $5.1 | 11.4% |
| Segment | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $150.2 | $140.6 | $9.5 | 6.8% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $50.2 | |
| Cost of Sales | $10.5 | 20.9% |
| Sales and Marketing | $34.4 | 68.5% |
| General and Admin | $16.3 | 32.4% |
| R & D | $4.7 | 9.3% |
| Other | $0.6 | 1.2% |
| Net Earnings | ($16.3) | (32.4%) |
Treace Medical reported 3Q25 orthopedic sales of $50.2 million, up 11.4% compared to the third quarter of 2024. For the first nine months of the year, the company generated $150.2 million in orthopedic sales, up 6.8% compared to the prior period.
The company has spent 2025 expanding its portfolio so it could compete for 100% of bunion...
Treace Medical reported 3Q25 orthopedic sales of $50.2 million, up 11.4% compared to the third quarter of 2024. For the first nine months of the year, the company generated $150.2 million in orthopedic sales, up 6.8% compared to the prior period.
The company has spent 2025 expanding its portfolio so it could compete for 100% of bunion cases. While the strategy has generally worked (case volume up mid-single-digits in the third quarter), Treace experienced pressure on its Lapiplasty volumes as surgeons and patients shift toward minimally invasive osteotomies.
Additionally, the company’s survey of its surgeons indicated a 7% volume decline year-over-year as patients defer elective procedures, especially those with commercial insurance.
Finally, Treace benefitted from one-time stocking orders from distributors, pulling about $3 million forward from expected fourth quarter revenues.
All told, the headwinds caused Treace to revise its guidance downward to revenues between $211 million and $213 million, representing growth between 1% and 2%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 3Q25 | 3Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $50.2 | $45.1 | $5.1 | 11.4% |
| Segment | 9mo25 | 9mo24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $150.2 | $140.6 | $9.5 | 6.8% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $50.2 | |
| Cost of Sales | $10.5 | 20.9% |
| Sales and Marketing | $34.4 | 68.5% |
| General and Admin | $16.3 | 32.4% |
| R & D | $4.7 | 9.3% |
| Other | $0.6 | 1.2% |
| Net Earnings | ($16.3) | (32.4%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
